A Real World Data of Ocrelizumab in Multiple Sclerosis

被引：0
|
作者：
Beckmann, Y.
Uzunkopru, C.
机构：
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1240
引用
收藏
页码：671 / 671
页数：1
相关论文
共 50 条
  • [31] Ocrelizumab for multiple sclerosis
    Lin, Mengbing
    Zhang, Jian
    Zhang, Yueling
    Luo, Jiefeng
    Shi, Shengliang
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (05):
  • [32] Ocrelizumab two-year real-world safety and effectiveness over in the treatment of multiple sclerosis
    Vollmer, Brandi
    Ijadi, Nassim
    Declusin, Anthony
    Nair, Kavita
    Sillau, Stefan
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2021, 96 (15)
  • [33] Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience
    Cellerino, M.
    Boffa, G.
    Lapucci, C.
    Sbragia, E.
    Bruschi, N.
    Mancuso, E.
    Tazza, F.
    Poire, I.
    Laroni, A.
    Capello, E.
    Uccelli, A.
    Novi, G.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 295 - 295
  • [34] Real-world experience with Ocrelizumab in Multiple Sclerosis patients: Two years follow up in Qatar
    Yousuf, Wajiha
    Ganesan, Gowrii Saswathy
    Humos, Basel
    Baig, Tehniyat
    Canibano, Beatriz
    Deleu, Dirk
    NEUROLOGY, 2021, 96 (15)
  • [35] A real-world analysis of ocrelizumab treatment patterns among multiple sclerosis patients in saskatchewan, canada
    Saini, A.
    Poliakov, I.
    Knox, K.
    Kahovec, C.
    Jata, A.
    Macgowan, S.
    Levin, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 323 - 323
  • [36] Switching from ocrelizumab to cladribine: real world data
    O'Neill, D.
    Sharma, M.
    Gonzales, B.
    Vandenheuval, M.
    Tse, B.
    Hodgkinson, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 67 - 68
  • [37] Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
    Chisari, Clara G.
    Bianco, Assunta
    Morra, Vincenzo Brescia
    Calabrese, Massimiliano
    Capone, Fioravante
    Cavalla, Paola
    Chiavazza, Carlotta
    Comi, Cristoforo
    Danni, Maura
    Filippi, Massimo
    Iaffaldano, Pietro
    Lanzillo, Roberta
    Lo Fermo, Salvatore
    Lucisano, Alessandra
    Lugaresi, Alessandra
    Lus, Giacomo
    Marfia, Gerolama Alessandra
    Marinelli, Fabiana
    Mirabella, Massimiliano
    Moiola, Lucia
    Perin, Chiara
    Realmuto, Sabrina
    Toscano, Simona
    Trojano, Maria
    Vecchio, Domizia
    Patti, Francesco
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1696 - 1706
  • [38] Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience
    Cellerino, Maria
    Boffa, Giacomo
    Lapucci, Caterina
    Sbragia, Elvira
    Bruschi, Nicolo
    Mancuso, Elisabetta
    Tazza, Francesco
    Poire, Ilaria
    Laroni, Alice
    Capello, Elisabetta
    Uccelli, Antonio
    Novi, Giovanni
    Inglese, Matilde
    NEUROLOGY, 2021, 96 (15)
  • [39] Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
    Clara G. Chisari
    Assunta Bianco
    Vincenzo Brescia Morra
    Massimiliano Calabrese
    Fioravante Capone
    Paola Cavalla
    Carlotta Chiavazza
    Cristoforo Comi
    Maura Danni
    Massimo Filippi
    Pietro Iaffaldano
    Roberta Lanzillo
    Salvatore Lo Fermo
    Alessandra Lucisano
    Alessandra Lugaresi
    Giacomo Lus
    Gerolama Alessandra Marfia
    Fabiana Marinelli
    Massimiliano Mirabella
    Lucia Moiola
    Chiara Perin
    Sabrina Realmuto
    Simona Toscano
    Maria Trojano
    Domizia Vecchio
    Francesco Patti
    Neurotherapeutics, 2023, 20 (6) : 1696 - 1706
  • [40] Wearing-off effect reports of people with multiple sclerosis treated with ocrelizumab in Canada: a descriptive summary of real-world data
    Morrow, S.
    Gitman, V.
    Rassi, J.
    Pasquarelli, N.
    Fitovski, K.
    Vorobeychik, G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 680 - 681
12345